SHPH

Shuttle Pharmaceuticals Inc

SHPH, USA

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.

https://www.shuttlepharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SHPH
stock
SHPH

What Does the Market Think About Shuttle Pharmaceuticals Holdings Inc? Benzinga

Read more →
SHPH
stock
SHPH

Crypto: SHPH at Critical Level: Why This Week Matters InteractiveCrypto

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.37

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-168.37 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-66.25 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.54

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.52% of the total shares of Shuttle Pharmaceuticals Inc

1.

UBS Group AG

(0.3144%)

since

2025/06/30

2.

Fidelity Extended Market Index

(0.1674%)

since

2025/07/31

3.

Fidelity Nasdaq Composite Index

(0.0247%)

since

2025/07/31

4.

Tower Research Capital LLC

(0.0115%)

since

2025/06/30

5.

Bank of America Corp

(0.0003%)

since

2025/06/30

7.

Barclays PLC

(0%)

since

2025/03/31

8.

Geode Capital Management, LLC

(0%)

since

2025/06/30

9.

Armistice Capital, LLC

(0%)

since

2025/06/30

10.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/06/30

11.

Citadel Advisors Llc

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.05

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.